Abstract

Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF

Author(s): Allen Loyd V Jr

Issue: Jul/Aug 2020 - Volume 24, Number 4

Page(s): 316

Download in electronic PDF format for $75

Abstract

A formulation for preparing Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2020 Pg. 316	Hydroxychloroquine Sulfate 25 mg/mL in Ora-Plus:Ora-Sweet SF Author(s): Allen Loyd V Jr
Nov/Dec 2017 Pg. 494	Hydroxychloroquine Sulfate 25 mg/mL in Oral Mix or Oral Mix SF Author(s): Allen Loyd V Jr
Jul/Aug 2001 Pg. 310-312	Wetting and/or Solubilizing Agents, Featured Excipient: Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 287-295	Pharmacies on the Frontline: Responding to the COVID-19 Pandemic Author(s): McElhiney Linda F
May/Jun 2023 Pg. 192-200	Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development Author(s): Riepl Mike, Kaiser Joe
Jan/Feb 2015 Pg. 66	Hydroxychloroquine Sulfate 200-mg Capsules Author(s): Allen Loyd V Jr
May/Jun 2017 Pg. 251-254	Stability of Extemporaneously Prepared Hydroxychloroquine Sulfate 25-mg/mL Suspensions in Plastic Bottles and Syringes Author(s): McHenry Adam R, Wempe Michael F, Rice Peter J
Jan/Feb 2023 Pg. 12-21	Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants Author(s): Riepl Mike
Mar/Apr 2021 Pg. 144	Eslicarbazepine Acetate 40-mg/mL in Ora-Plus with Ora-Sweet or Ora-Sweet SF Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2023 Pg. 284-293	Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID Author(s): Riepl Mike, Kaiser Joe
Sep/Oct 2023 Pg. 368-380	Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023 Pg. 98-107	Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment Author(s): Riepl Mike
Jul/Aug 2020 Pg. 268	PreScription: COVID-19 and Compounding Pharmacists Author(s): Allen Loyd V Jr
Sep/Oct 2019 Pg. 413	Verapamil Hydrochloride 50 mg/mL in Ora-Plus:Ora-Sweet (1:1) Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 496	Hydroxyurea 100 mg/mL in Ora-Plus:Ora-Sweet, Ora-Plus: Ora-Sweet SF, Ora-Blend or Oral-Blend SF Oral Suspensions Author(s): Allen Loyd V Jr
Jan/Feb 2019 Pg. 57	Minoxidil 1-mg/mL in Ora-Plus and Ora-Sweet SF Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2023 Pg. 53	Erlotinib 10 mg/mL in Ora-Sweet and Ora-Plus Author(s): Allen Loyd V Jr
Jan/Feb 2018 Pg. 51	Mercaptopurine 50 mg/mL in Ora-Sweet and Ora-Plus Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2018 Pg. 58	Thalidomide 20 mg/mL in Ora-Plus and Ora-Sweet Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2023 Pg. 52	Dapsone 2 mg/mL in Ora-Sweet and Ora-Plus Author(s): Allen Loyd V Jr